New England Journal of Medicine Publishes New Data for Genentech's Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
Portfolio Pulse from
Genentech's Gazyva shows significant improvement in treating active lupus nephritis, according to a Phase III trial published in the New England Journal of Medicine.
February 07, 2025 | 9:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genentech, part of Roche Group, announced positive Phase III trial results for Gazyva in treating lupus nephritis, published in NEJM.
The publication of positive Phase III trial results in a reputable journal like NEJM is likely to boost investor confidence in Genentech's Gazyva, potentially leading to an increase in Roche's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80